EASL-EASD-EASO guidance recommends resmetirom or semaglutide, alongside lifestyle intervention, for adults with non-cirrhotic MASH and fibrosis stages 2-3; semaglutide may be preferred with obesity, T2D or cardiovascular risk. Not advised as MASH treatment in cirrhosis.
Guideline
European Association for the Study of Obesity (EASO). Electronic address: [email protected] EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy